MedTrace Logo

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

NCT00219791 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-09-11

No results posted yet for this study

Summary

To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate (MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with intrathecal MTX overdose.

Conditions

  • Neoplasms

Interventions

DRUG

glucarpidase (50 Units/kg)

Sponsors & Collaborators

  • BTG International Inc.

    lead OTHER

Principal Investigators

  • Thiel Eckhard, Prof. Dr.med. · Charite - Universitätsmedizin Berlin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Completion
2003-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219791 on ClinicalTrials.gov